AbbVie Inc ABBV Submits SKYRIZI Subcutaneous Crohns Regimen to FDA But NearTerm Upside Remains Capped By Competitive Risks SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading ZURA Zura Bio posts far wider Q4 2025 loss than consensus estimates sending its shares down 254 today